Mehran R, Pocock SJ, Stone GW et al (2009) Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart 30:1457–1466. https://doi.org/10.1093/eurheartj/ehp110

Article  Google Scholar 

Valgimigli M, Costa F, Lokhnygina Y et al (2017) Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J 38:804–810. https://doi.org/10.1093/eurheartj/ehw525

Article  CAS  PubMed  Google Scholar 

Gorog DA, Ferreiro JL, Ahrens I et al (2023) De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a consensus statement from an international expert panel on coronary thrombosis. Nat Rev Cardiol. https://doi.org/10.1038/s41569-023-00901-2

Article  PubMed  Google Scholar 

Varenhorst C, Lindholm M, Sarno G et al (2018) Stent thrombosis rates the first year and beyond with new- and old-generation drug-eluting stents compared to bare metal stents. Clin Res Cardiol 107:816–823. https://doi.org/10.1007/s00392-018-1252-0

Article  PubMed  PubMed Central  Google Scholar 

Sibbing D, Aradi D, Alexopoulos D et al (2019) Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv 12:1521–1537. https://doi.org/10.1016/jcin.2019.03.034

Article  PubMed  Google Scholar 

Aradi D, Kirtane A, Bonello L et al (2015) Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 36:1762–1771. https://doi.org/10.1093/eurheartj/ehv104

Article  CAS  PubMed  Google Scholar 

Angiolillo DJ, Rollini F, Storey RF et al (2017) International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation 136:1955–1975. https://doi.org/10.1161/CIRCULATIONAHA.117.031164

Article  CAS  PubMed  Google Scholar 

Galli M, Franchi F, Rollini F, Angiolillo DJ (2021) Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention. Trends Cardiovasc Med. https://doi.org/10.1016/j.tcm.2021.12.007

Article  PubMed  Google Scholar 

Hahn JY, Song YB, Oh JH, SMART-DATE investigators et al (2018) 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet 391(10127):1274–1284. https://doi.org/10.1016/S0140-6736(18)30493-8

Article  PubMed  Google Scholar 

Kedhi E, Fabris E, van der Ent M et al (2018) Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ 363:k3793. https://doi.org/10.1136/bmj.k3793

Article  PubMed  PubMed Central  Google Scholar 

De Luca G, Damen SA, Camaro C et al (2019) Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial). EuroIntervention 15:e990–e998. https://doi.org/10.4244/EIJ-D-19-00539

Article  PubMed  Google Scholar 

Kim BK, Hong SJ, Cho YH, Investigators TICO et al (2020) Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO Randomized Clinical Trial. JAMA 323:2407–2416. https://doi.org/10.1001/jama.2020.7580

Article  CAS  PubMed  PubMed Central  Google Scholar 

Watanabe H, Morimoto T, Natsuaki M, STOP DAPT-2 ACS Investigators et al (2022) Comparison of clopidogrel monotherapy after 1–2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: The STOP DAPT-2 ACS Randomized Clinical Trial. JAMA Cardiol 7:407–417. https://doi.org/10.1001/jamacardio.2021.5244

Article  PubMed  PubMed Central  Google Scholar 

Vranckx P, Valgimigli M, Jüni P, GLOBAL LEADERS Investigators et al (2018) Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 392:940–949. https://doi.org/10.1016/S0140-6736(18)31858-0

Article  CAS  PubMed  Google Scholar 

Mehran R, Baber U, Sharma SK et al (2019) Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 381:2032–2042. https://doi.org/10.1056/NEJMoa1908419

Article  CAS  PubMed  Google Scholar 

Vranckx P, Valgimigli M, Odutayo A, GLOBAL LEADERS Investigators et al (2020) Efficacy and safety of ticagrelor monotherapy by clinical presentation: pre-specified analysis of the GLOBAL LEADERS trial. J Am Heart Assoc 10(18):e015560. https://doi.org/10.1161/JAHA.119.015560

Article  Google Scholar 

Baber U, Dangas G, Angiolillo DJ et al (2020) Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J 41:3533–3545. https://doi.org/10.1093/eurheartj/ehaa670

Article  CAS  PubMed  Google Scholar 

Selvaraj V, Chatterjee S, Hirai T, Abbott JD, Bavishi C (2022) Three versus 12-month dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Catheter Cardiovasc Interv 100:1151–1158. https://doi.org/10.1002/ccd.30467

Article  PubMed  Google Scholar 

Feng WH, Chang YC, Lin YH et al (2023) P2Y12 inhibitor monotherapy versus conventional dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention: a meta-analysis. Pharmaceuticals 16:232. https://doi.org/10.3390/ph16020232

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cuisset T, Deharo P, Quilici J et al (2017) Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 38:3070–3078. https://doi.org/10.1093/eurheartj/ehx175

Article  CAS  PubMed  Google Scholar 

Kim HS, Kang J, Hwang D, HOST-REDUCE-POLYTECH-ACS investigators et al (2020) Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet 396:1079–1089. https://doi.org/10.1016/S0140-6736(20)31791-8

Article  CAS  PubMed  Google Scholar 

Kim CJ, Park MW, Kim MC, TALOS-AMI investigators et al (2021) Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet 398:1305–1316. https://doi.org/10.1016/S0140-6736(21)01445-8

Article  CAS  PubMed  Google Scholar 

Cayla G, Cuisset T, Silvain J et al (2016) Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 388:2015–2022. https://doi.org/10.1016/S0140-6736(16)31323-X

Article  CAS  PubMed  Google Scholar 

Sibbing D, Aradi D, Jacobshagen C et al (2017) Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 390:1747–1757. https://doi.org/10.1016/S0140-6736(17)32155-4

Article  CAS  PubMed  Google Scholar 

Claasens DMF, Vos GJA, Bergmeijer TO et al (2019) A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med 381:1621–1631. https://doi.org/10.1056/NEJMoa1907096

Article  Google Scholar 

Galli M, Benenati S, Franchi F et al (2022) Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61,898 patients from 15 randomized trials. Eur Heart J 43:959–967. https://doi.org/10.1093/eurheartj/ehab836

Article  PubMed  Google Scholar 

Tavenier AH, Mehran R, Chiarito M et al (2022) Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis. Eur Heart J Cardiovasc Pharmacother 8:492–502. https://doi.org/10.1093/ehjcvp/pvab068

Article  PubMed  Google Scholar 

Kang J, Rizas KD, Park KW et al (2023) Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis. Eur Heart J 44:1360–1370. https://doi.org/10.1093/eurheartj/ehac829

Article  CAS  PubMed  Google Scholar 

Byrne RA, Rossello X, Coughlan JJ, ESC Scientific Document Group et al (2023) ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 44:3720–3826. https://doi.org/10.1093/eurheartj/ehad191

Article  CAS  PubMed  Google Scholar 

Laudani C, Greco A, Occhipinti G et al (2022) Short duration of DAPT versus de-escalation after percutaneous coronary intervention for acute coronary syndromes. JACC Cardiovasc Interv 15:268–277. https://doi.org/10.1016/j.jcin.2021.11.028

Article  PubMed  Google Scholar 

Kuno T, Watanabe A, Shoji S et al (2023) Short-term DAPT and DAPT de-escalation strategies for patients with acute coronary syndromes: a systematic review and network meta-analysis. Circ Cardiovasc Interv 16:e013242. https://doi.org/10.1161/CIRCINTERVENTIONS.123.013242

Article  PubMed  Google Scholar 

Galli M, Angiolillo DJ (2022) De-escalation of antiplatelet therapy in acute coronary syndromes: why, how and when? Front Cardiovasc Med 9:975969. https://doi.org/10.3389/fcvm.2022.975969

Article  CAS  PubMed  PubMed Central  Google Scholar 

Natsuaki M, Watanabe H, Takeshi Mori